This is a one-arm, open-label study to examine the effect of dupilumab. Dupilumab is a FDA-approved medication for the treatment of atopic dermatitis. This study will examine how dupilumab affects immune cells within atopic dermatitis skin lesions. Fifteen subjects with moderate to severe atopic dermatitis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict dupilumab treatment response.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. 18 years of age or older
2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
You may not be if
1. Known pregnancy
2. Known immunodeficiencies
3. Known parasitic infection -
Clareo Health | Molecular Signatures of Cutaneous Dupilumab Response
